Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,008.00-1.90%ETH$2,254.04-1.71%GOLD$3,960.80-0.22%OIL$96.52+0.06%
Smart Investors Daily
SID Premium
PC

NASDAQ · PCRX

Pacira BioSciences, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$36.39

Up+$0.01 (+0.03%)

Updated Nov 3, 2026, 12:56 AM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.17B
P/E ratio
38.27
Dividend yield
0.00%
52-week range
$21.16 – $36.67
Volume
737.24K
Avg. volume
635.91K

Price performance · PCRX

PCRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

PCRX closed at $36.39 after 20 trading sessions, up 45.27% for the selected period.

Last close
$36.39
Period change
+45.27%
Period low
$24.76
Period high
$36.42
Daily close
View OHLC price history
PCRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$36.40$36.43$36.38$36.39737.24K
Oct 29, 2026$36.39$36.40$36.365$36.39618.95K
Oct 28, 2026$36.38$36.40$36.35$36.39914.03K
Oct 27, 2026$36.38$36.42$36.38$36.40471.79K
Oct 26, 2026$36.38$36.45$36.365$36.38607.3K
Oct 23, 2026$36.33$36.42$36.33$36.42574.32K
Oct 22, 2026$36.38$36.40$36.31$36.341.05M
Oct 21, 2026$36.36$36.385$36.32$36.331.49M
Oct 20, 2026$36.39$36.425$36.33$36.381.05M
Oct 19, 2026$36.35$36.39$36.33$36.341.07M
Oct 16, 2026$36.38$36.39$36.32$36.34960.94K
Oct 15, 2026$36.39$36.665$36.31$36.332.06M
Oct 14, 2026$36.33$36.48$36.31$36.402.33M
Oct 13, 2026$36.35$36.35$36.30$36.312.22M
Oct 12, 2026$36.34$36.35$36.32$36.352.01M
Oct 9, 2026$36.33$36.355$36.31$36.314.69M
Oct 8, 2026$36.325$36.46$36.27$36.3928.9M
Oct 7, 2026$25.05$26.00$24.99$25.20802.73K
Oct 6, 2026$25.13$25.25$24.56$24.76493.12K
Oct 5, 2026$25.37$25.71$24.83$25.05560.25K

Latest PCRX news

The latest Smart Investors Daily articles mentioning PCRX.

Stock researchCompany · Overview

PCRX research

Overview

Company profile and research snapshot.

Company profile

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$27.00
Implied upside
—
Analysts
13
PCRX recent ratings
DateFirmRatingTarget
Oct 9, 2026HC Wainwright & Co.Neutral—
Oct 9, 2026RBC CapitalSector Perform—
Oct 9, 2026Truist SecuritiesHold—
Oct 8, 2026JP MorganNeutral—
Oct 8, 2026JefferiesHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing

The latest update on Pacira BioSciences lifts the modelled fair value from US$30.00 to about US$33.57 per share, a mid single digit change that reframes where some analysts see the stock settling. With coverage now centered on the agreed US$36.50 per share cash acquisition by Viatris and the question of any remaining upside to that deal price, this new target range helps anchor how research desks are talking about potential outcomes. As you read on, you will see how to track this evolving...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By